Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Moderna Begins Study of Omicron-Specific Vaccine Booster

Jan. 26, 2022, 10:05 PM

Moderna Inc. enrolled the first participant in a clinical trial of its omicron-specific vaccine booster, another step toward fighting the highly transmissible variant that’s spread around the world in a matter of weeks.

Moderna and rival Pfizer Inc. are each rushing to test omicron-specific vaccines in case they are needed as the variant continues to pummel the globe. Moderna’s statement on the new trial comes just one day after Pfizer said it had began a 1,400-person study of a messenger RNA shot targeted against omicron.

The Moderna study will test an omicron-specific booster called mRNA-1273.529 in 600 adults who have ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.